Effect of a Probiotic Preparation (VSL#3) on Induction and Maintenance of Remission in Children With Ulcerative Colitis
- 20 January 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in The American Journal of Gastroenterology
- Vol. 104 (2), 437-443
- https://doi.org/10.1038/ajg.2008.118
Abstract
Several probiotic compounds have shown promise in the therapy of ulcerative colitis (UC). However, a strong sustained benefit remains to be seen. Uncontrolled pilot studies suggest that a probiotic preparation (VSL#3) maintains remission in mild to moderate UC and reduces active inflammation in adult patients. Aims of our prospective, 1-year, placebo-controlled, double-blind study were to assess the efficacy of VSL#3 on induction and maintenance of remission and to evaluate the safety and tolerability of the probiotic preparation therapy in children with active UC. A total of 29 consecutive patients (mean age: 9.8 years; range: 1.7–16.1 years; female/male: 13/16) with newly diagnosed UC were randomized to receive either VSL#3 (weight-based dose, range: 450–1,800 billion bacteria/day; n=14) or an identical placebo (n=15) in conjunction with concomitant steroid induction and mesalamine maintenance treatment. Children were prospectively evaluated at four time points: within 1 month, 2 months, 6 months, and 1 year after diagnosis or at the time of relapse. Lichtiger colitis activity index and a physician's global assessment were used to measure disease activity. At baseline, within 6 months and 12 months or at the time of relapse, all patients were assessed endoscopically and histologically. All 29 patients responded to the inflammatory bowel disease (IBD) induction therapy. Remission was achieved in 13 patients (92.8%) treated with VSL#3 and IBD therapy and in 4 patients (36.4%) treated with placebo and IBD therapy (PP=0.014; RR=0.32; CI=0.025–0.773; NNT=2). All 3 patients treated with VSL#3 and 6 of 11 (54.5%) patients treated with placebo relapsed within 6 months of diagnosis. At 6 months, 12 months, or at time of relapse, endoscopic and histological scores were significantly lower in the VSL#3 group than in the placebo group (P<0.05). There were no biochemical or clinical adverse events related to VSL#3. This is the first pediatric, randomized, placebo-controlled trial that suggests the efficacy and safety of a highly concentrated mixture of probiotic bacterial strains (VSL#3) in active UC and demonstrates its role in maintenance of remission.Keywords
This publication has 35 references indexed in Scilit:
- Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapyGut, 2008
- Microbial Influences in Inflammatory Bowel DiseasesGastroenterology, 2008
- VSL#3 probiotic upregulates intestinal mucosal alkaline sphingomyelinase and reduces inflammationCanadian Journal of Gastroenterology, 2008
- The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cellsAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2007
- The Natural History of Corticosteroid Therapy for Ulcerative Colitis in ChildrenClinical Gastroenterology and Hepatology, 2006
- VSL#3: An Analysis of Basic and Clinical Contributions in Probiotic TherapeuticsGastroenterology Clinics of North America, 2005
- Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trialGastroenterology, 2000
- Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel diseaseGastroenterology, 2000
- INFLAMMATORY BOWEL DISEASE IN PEDIATRIC AND ADOLESCENT PATIENTSGastroenterology Clinics of North America, 1999
- Probiotics in man and animalsJournal of Applied Bacteriology, 1989